News

Sectoral Asset Management led the round, which included participants such as Novo A/S, Aisling Capital and Brace Pharma Capital. Existing investors Advent Life Sciences, Novartis Venture Fund, Sunstone

Eflornithine is a novel cytostatic agent, which is being developed to treat patients with recurrent anaplastic astrocytoma, a rare form of central nervous system cancer. The drug irreversibly

The acquired portfolio includes products that are being divested by Teva as a precondition to its closing of the acquisition of Allergan’s generics business. Acquisition Highlights Sagent has

The new partnership, ‘Arkin Bio-Ventures’ (51% Arkin Holdings and 49% Phoenix) aims to invest in companies that develop promising innovative pharmaceuticals in pre-clinical and more advanced stages, both

The partnership brings together Cantabio’s novel approach and the University of Antioquia’s research excellence on the role of oxidative stress in PD and other neurodegenerative diseases. Pharmaceutical chaperones

The Company expects to report top-line results from this study in the fourth quarter of 2016. Principal Investigator Robert Spiera, M.D., Director of the Vasculitis and Scleroderma Program

PreserVision is the #1 doctor-recommended eye vitamin brand specially formulated for people with moderate to advanced Age-Related Macular Degeneration. The 2-in-1 formula helps make it simpler for consumers

Proceeds from the financing will be used to advance the selection and development of lead molecules designed to modify the pathobiology of fibrotic diseases. The round included new

"In response to the growing demand for Immuno-Oncology translational services, CrownBio is now able to offer at its local facilities immunophenotyping analysis, including multi-color flow cytometry, immunohistochemistry and